Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

BDMPEA 2-(4-bromo-2,5-dimethoxy- phenyl)ethanamine

Synonyms: SureCN23478, CHEMBL292821, AG-G-49202, CHEBI:189669, CTK2F5078, ...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of BDMPEA

4-Bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive designer drug of abuse that is sold under the street names "Venus", "Bromo", "Erox", "XTC" or "Nexus". Concern has been raised because only little is known about its toxicity and metabolism in humans [1].

High impact information on BDMPEA

4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes [2].
The metabolism of methamphetamine (MA) and 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in freshly isolated rat hepatocytes was investigated, and compared with in vivo results [3].
The effects of 4-bromo-2,5-dimethoxyphenethylamine (Nexus), 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxyphenyl-2-butanamine (BDB), and cathinone were studied in the newly hatched chicken and compared to the effects of d-amphetamine and three hallucinogens in the same species [4].
1. 2C-B [2-(4-bromo-2,5-dimethoxyphenyl)ethylamine] elicits concentration-dependent contraction of the rat thoracic aorta (apparent pD2 = 4.55) [5].

Anatomical context of BDMPEA

Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human [1].

Analytical, diagnostic and therapeutic context of BDMPEA

This study sought to identify, by means of several analytical methods (GC-MS, HPLC-DAD, CE-DAD, FTIR, and NMR), 4-bromo-2,5-dimethoxyphenethylamine (2C-B), which was found in two sets of tablets obtained from the Swiss black market [6].

References

Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Carmo, H., Hengstler, J.G., de Boer, D., Ringel, M., Remião, F., Carvalho, F., Fernandes, E., dos Reys, L.A., Oesch, F., de Lourdes Bastos, M. Toxicology (2005) [Pubmed]
4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Villalobos, C.A., Bull, P., Sáez, P., Cassels, B.K., Huidobro-Toro, J.P. Br. J. Pharmacol. (2004) [Pubmed]
A study of the metabolism of methamphetamine and 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in isolated rat hepatocytes. Kanamori, T., Tsujikawa, K., Ohmae, Y., Iwata, Y.T., Inoue, H., Kishi, T., Nakahama, T., Inouye, Y. Forensic Sci. Int. (2005) [Pubmed]
A behavioral comparison of Nexus, cathinone, BDB, and MDA. Bronson, M.E., Jiang, W., DeRuiter, J., Clark, C.R. Pharmacol. Biochem. Behav. (1995) [Pubmed]
The action of the psychoactive drug 2C-B on isolated rat thoracic aorta. Lobos, M., Borges, Y., Gonzalez, E., Cassels, B.K. Gen. Pharmacol. (1992) [Pubmed]
2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the Swiss black market. Giroud, C., Augsburger, M., Rivier, L., Mangin, P., Sadeghipour, F., Varesio, E., Veuthey, J.L., Kamalaprija, P. Journal of analytical toxicology. (1998) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg